Download MendeleyDiscovery of a Novel Series of Imidazopyrazine Derivatives as Potent SHP2 Allosteric Inhibitors.
Torrente, E., Fodale, V., Ciammaichella, A., Ferrigno, F., Ontoria, J.M., Ponzi, S., Rossetti, I., Sferrazza, A., Amaudrut, J., Missineo, A., Esposito, S., Palombo, S., Nibbio, M., Cerretani, M., Bisbocci, M., Cellucci, A., di Marco, A., Alli, C., Pucci, V., Toniatti, C., Petrocchi, A.(2023) ACS Med Chem Lett 14: 156-162
- PubMed: 36793438 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1021/acsmedchemlett.2c00454
- Primary Citation Related Structures:
8B5Y, 8CBH - PubMed Abstract:
Protein tyrosine phosphatase SHP2 is an oncogenic protein that can regulate different cytokine receptor and receptor tyrosine kinase signaling pathways. We report here the identification of a novel series of SHP2 allosteric inhibitors having an imidazopyrazine 6,5-fused heterocyclic system as the central scaffold that displays good potency in enzymatic and cellular assays. SAR studies led to the identification of compound 8 , a highly potent SHP2 allosteric inhibitor. X-ray studies showed novel stabilizing interactions with respect to known SHP2 inhibitors. Subsequent optimization allowed us to identify analogue 10 , which possesses excellent potency and a promising PK profile in rodents.
- Department of Drug Discovery IRBM S.p.A., Pomezia, Rome 00071, Italy.
Organizational Affiliation:
